The 2026 evidence base for regenerative medicine.

Compared with small molecules, peptides pair receptor selectivity with a favorable safety profile — reducing off-target toxicity while retaining the potency needed for chronic disease management. Compared with biologics, they are cheaper to manufacture, easier to formulate, and can often be self-administered subcutaneously.

For 2026 practice, DRS tracks four evidence tiers: (1) FDA-approved peptide drugs, (2) compounded peptides prescribed under state pharmacy rules, (3) research-grade peptides under active investigator-initiated trials, and (4) preclinical candidates with published mechanism-of-action data. Every protocol recommended through PepEdHub cites the tier and the primary literature it draws from.

In SURMOUNT-1, tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% for placebo — the largest effect observed for a non-surgical intervention at that time. In 2023, retatrutide (a GLP-1 / GIP / glucagon triple agonist) delivered 24.2% mean weight loss at 48 weeks in TRIUMPH-1, with the highest-dose arm still trending downward at study end.

Beyond weight, SELECT (17,604 adults with cardiovascular disease and BMI ≥ 27) established that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo — the first cardiovascular outcomes benefit for a GLP-1 in patients without diabetes. 2026 practice increasingly frames these agents as cardiometabolic therapies, not weight-loss drugs.

For chronic plantar fasciitis, pooled Cochrane data show focused ECSWT achieves clinically meaningful pain reduction at 12 weeks in roughly two-thirds of patients — comparable to corticosteroid injection at short-term follow-up but with durability advantages at six months. In vasculogenic erectile dysfunction, low-intensity ECSWT produced a mean IIEF-5 improvement of approximately four points versus sham, per a European Urology meta-analysis of 14 randomized trials.

Cardiac shockwave has the deepest European evidence base: multi-center registries in Austria, Germany, and Japan report reduced angina class and improved perfusion in refractory ischemic heart disease at 6- and 12-month follow-up, without the bleeding risk profile of repeat revascularization.

A landmark Lancet meta-analysis established laser therapy's efficacy for neck pain (VAS reduction of approximately 20 mm versus sham), and subsequent WALT dosage tables give reproducible per-condition parameters clinicians can audit. HPLT's advantage over lower-power devices is treatment time, not mechanism: a 10 J/cm² dose that requires 8 minutes at 500 mW takes under 60 seconds at 15 W, enabling deeper tissue penetration within clinical workflow.

In post-surgical rehabilitation, VA and DoD studies report faster return-to-duty timelines and reduced opioid utilization when HPLT is integrated with standard physical therapy. Contraindications remain narrow: active malignancy in the treatment field, thyroid tissue, and gravid uterus.

Perinatal MSCs are collected non-invasively at scheduled Cesarean delivery from healthy, screened donors — no adipose harvest, no bone-marrow aspiration, and no age-related decline in proliferative capacity. Comparative 2024 Cytotherapy data show Wharton's jelly MSCs secrete substantially higher VEGF, HGF, and TSG-6 than autologous bone-marrow MSCs from donors over 55.

All perinatal biologics distributed through DRS come from FDA-registered tissue banks operating under 21 CFR Part 1271, with documented HCT/P compliance, donor eligibility records, and lot-level release testing (sterility, endotoxin, mycoplasma, viability).

Randomized trials in diabetic foot ulcer (DFU) show approximately 85% complete closure at 12 weeks with weekly amniotic allograft application versus about 50% with standard of care. In ophthalmology, cryopreserved amniotic membrane remains a first-line adjunct for persistent epithelial defects, chemical burns, and pterygium surgery.

Orthopedic use continues to expand — the 2020 Placenta journal proteomics survey identified more than 220 distinct growth factors and cytokines in amniotic tissue, providing mechanistic support for its use in tendinopathy, joint capsule augmentation, and post-arthroscopic protocols.

DRS-distributed exosome products are characterized against MISEV 2023: nanoparticle tracking analysis for size distribution and concentration, flow cytometry or western blot for tetraspanin surface markers (CD9, CD63, CD81), and negative markers (calnexin) to demonstrate absence of cellular contamination. Each lot ships with a Certificate of Analysis reflecting this workup.

MISEV 2023 tightens language around what may be called an 'exosome' versus a generic 'small extracellular vesicle' (sEV). This matters clinically: many products marketed as exosomes fail to meet the size, surface marker, and purity criteria required to claim biogenesis of endosomal origin. DRS provides only preparations that meet full MISEV 2023 reporting.

As of August 2024, the FDA had cleared more than 950 AI/ML-enabled medical devices — a fivefold increase over 2020. The regulatory conversation has shifted from 'can AI be a medical device?' to 'how do we govern iterative model updates in already-cleared devices?' — reflected in the FDA's 2023 Predetermined Change Control Plan guidance.

PeptideProtocols.ai and Dr. Peptide operate as decision-support tools for licensed providers, not autonomous prescribers: every recommendation cites the underlying evidence tier, includes contraindication checks against the patient's active medication list, and logs the reviewing clinician's final decision. Collective intelligence across the provider network feeds anonymized outcome data back into protocol refinement.